IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJohann Wolfgang Goethe University Hospital

About this trial

Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).

Eligibility criteria

Qualifiers

Able to provide informed consent

18 years of age and over

Absence of a valid clinical indication for CMR, and/or known or clinically relevant cardiac disease

Disqualifiers

accepted contraindications for a contrast-enhanced CMR study (in line with MRI safety and SmPC for contrast agent)

Trial design

Treatments tested in this trial

  • Cardiac Imaging

Treatment groups

No treatment groups listed